Literature DB >> 2538270

Conditions favoring long-term survival after hepatectomy for hepatocellular carcinomas.

N Yamanaka1, E Okamoto.   

Abstract

The present study was aimed at answering the question of what patients with hepatocellular carcinomas could obtain long-term benefits from resectional therapy. The 239 patients hepatectomized from 1973 through 1986, with 33 tumor-free, 3-year survivors, were the subjects of the study. The following criteria for long-term survival were determined. (a) It is essential that there are no macroscopic tumor thrombi in any of the vessels. (b) It is desirable that there is no daughter lesion and a tumor size of less than 5 cm. (c) When there are daughter lesions, they should be confined to the region adjacent to the main tumor and only few in number. (d) Resection should be performed on a large scale within the limit of safety, especially for the tumors with daughter lesions. (e) The surgical margin should be free of tumor though the exposure of the tumor capsule is not always incompatible with long survival.

Entities:  

Mesh:

Year:  1989        PMID: 2538270     DOI: 10.1007/bf00647247

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Results of surgical treatments of primary hepatocellular carcinoma: some aspects to improve long-term survival.

Authors:  E Okamoto; N Tanaka; N Yamanaka; A Toyosaka
Journal:  World J Surg       Date:  1984-06       Impact factor: 3.352

2.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

3.  Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function.

Authors:  E Okamoto; A Kyo; N Yamanaka; N Tanaka; K Kuwata
Journal:  Surgery       Date:  1984-05       Impact factor: 3.982

4.  A multiple regression equation for prediction of posthepatectomy liver failure.

Authors:  N Yamanaka; E Okamoto; K Kuwata; N Tanaka
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

  4 in total
  7 in total

1.  Hepatic resection for small hepatocellular carcinoma: the Queen Mary Hospital experience.

Authors:  E C Lai; I O Ng; K T You; S T Fan; F P Mok; E S Tan; J Wong
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

2.  The pathological basis of resection margin for hepatocellular carcinoma.

Authors:  E C Lai; K T You; I O Ng; T W Shek
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

3.  Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization.

Authors:  K S Jeng; F S Yang; H J Chiang; I Ohta
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

4.  En bloc resection for extensive hepatocellular carcinoma: is it advisable?

Authors:  K S Jeng; B F Chen; H J Lin
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

5.  Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients.

Authors:  Paolo Sorrentino; Salvatore D'Angelo; Luciano Tarantino; Umberto Ferbo; Alessandra Bracigliano; Raffaela Vecchione
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

6.  Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Yi-Chun Tsai
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

7.  Rapidly progressive hepatocellular carcinoma mimicking benign portal vein thrombosis: a case report.

Authors:  Jin Woong Kim; Byung Chan Lee; Sang Soo Shin; Suk Hee Heo; Hyo Soon Lim; Yong Yeon Jeong; Heoung Keun Kang; Young Hoe Hur; Yoo Duk Choi
Journal:  Gut Liver       Date:  2013-01-11       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.